The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Open accessAbstract
PURPOSE: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC). METHODS: ASCO convened an Expert Panel to update the 2020 guideline on systemic therapy for HCC. The panel updated the systematic review to include randomized controlled trials (RCTs) published through October 2023 and updated recommendations. RESULTS: Ten new RCTs met the inclusion criteria and were added to the evidence base. RECOMMENDATIONS: Atezolizumab + bevacizumab (atezo + bev) or durvalumab + tremelimumab (durva + treme) may be offered first-line for patients with advanced HCC, Child-Pugh class A liver disease, and Eastern Cooperative Oncology Group performance status 0-1. Where there are contraindications to these therapies, sorafenib, lenvatinib, or durvalumab may be offered first-line. Following first-line treatment with atezo + bev, second-line therapy with a tyrosine kinase inhibitor (TKI), ramucirumab (for patients with alpha-fetoprotein [AFP] ≥400 ng/mL), durva + treme, or nivolumab + ipilimumab (nivo + ipi) may be recommended for appropriate candidates. Following first-line therapy with durva + treme, second-line therapy with a TKI is recommended. Following first-line treatment with sorafenib or lenvatinib, second-line therapy options include cabozantinib, regorafenib for patients who previously tolerated sorafenib, ramucirumab (AFP ≥400 ng/mL), nivo + ipi, or durvalumab; atezo + bev or durva + treme may be considered for patients who did not have access to these therapies in the first-line setting, and do not have contraindications. Pembrolizumab or nivolumab are also options for appropriate patients following sorafenib or lenvatinib. Third-line therapy may be considered in Child-Pugh class A patients with good PS, using one of the agents listed previously that has a nonidentical mechanism of action with previously received therapy. A cautious approach to systemic therapy is recommended for patients with Child-Pugh class B advanced HCC. Further guidance on choosing between options is included within the guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationVillanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Self-citationZhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationCabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Self-citationFerrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1474 · Cited by 2,117
Global Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3055 · Cited by 1,987
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Self-citationCheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
Self-citationZhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Self-citationTremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576
Self-citationPhase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Self-citationRen, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124
Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00604-5 · Cited by 1,106
Self-citationYau, T. (., Park, J. W. (.-W., Finn, R. S. (. S. )., Cheng, A. L. (.-L., Mathurin, P., Edeline, J., Kudo, M. (., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · Cited by 934
Self-citationFinancial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Ramsey, S. D., Bansal, A., Fedorenko, C. R., Blough, D. K., Overstreet, K. A., Shankaran, V., & Newcomb, P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.6620 · Cited by 912
Zhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Self-citationKudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., Nojiri, S., Hino, K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318934 · Cited by 721
Yau, T., Park, J. W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Han, K.-H., Harding, J. J., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.029 · Cited by 647
Self-citationAmerican Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Patient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P., Goff, L., Gupta, S., Guy, J., Harris, W. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02672 · Cited by 570
Self-citationKelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00326-6 · Cited by 535
Self-citationCost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Peng, Z., Fan, W., Zhu, B., Wang, G., Sun, J., Xiao, C., Huang, F., Tang, R., Cheng, Y., Huang, Z., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00392 · Cited by 460
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
Petrick, J. L., Kelly, S. P., Altekruse, S. F., McGlynn, K. A., & Rosenberg, P. S. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.7412 · Cited by 442
Qin, S., Bi, F., Gu, S., Bai, Y., Chen, Z., Wang, Z., Ying, J., Lu, Y., Meng, Z., Pan, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00163 · Cited by 409
Marrero, J. A., Kudo, M., Venook, A. P., Ye, S.-L., Bronowicki, J.-P., Chen, X.-P., Dagher, L., Furuse, J., Geschwind, J.-F. H., de Guevara, L. L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.020 · Cited by 385
Finn, R. S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.010 · Cited by 347
Self-citationBrożek, J. L., Akl, E. A., Compalati, E., Kreis, J., Terracciano, L., Fiocchi, A., Ueffing, E., Andrews, J., Alonso-Coello, P., Meerpohl, J. J., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02530.x · Cited by 297
Qin, S., Kudo, M., Meyer, T., Bai, Y., Guo, Y., Meng, Z., Satoh, T., Marino, D., Assenat, E., Li, S., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4003 · Cited by 265
Self-citationGriggs, J., Maingi, S., Blinder, V., Denduluri, N., Khorana, A. A., Norton, L., Francisco, M., Wollins, D. S., & Rowland, J. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.0441 · Cited by 261
Qin, S., Li, Q., Gu, S., Chen, X., Lin, L., Wang, Z., Xu, A., Chen, X., Zhou, C., Ren, Z., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00109-6 · Cited by 252
Artinyan, A., Mailey, B., Sanchez‐Luege, N., Khalili, J., Sun, C., Bhatia, S., Wagman, L. D., Nissen, N., Colquhoun, S. D., & Kim, J. (2010) · Cancer · doi:10.1002/cncr.24817 · Cited by 250
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
D’Alessio, A., Fulgenzi, C. A. M., Nishida, N., Schönlein, M., von Felden, J., Schulze, K., Wege, H., Gaillard, V. E., Saeed, A., Wietharn, B., et al. (2022) · Hepatology · doi:10.1002/hep.32468 · Cited by 235
Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer
Gilligan, A. M., Alberts, D. S., Roe, D. J., & Skrepnek, G. H. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.05.020 · Cited by 232
Kudo, M., Matilla, A., Santoro, A., Melero, I., Gracián, A. C., Acosta-Rivera, M., Choo, S.-P., El-Khoueiry, A. B., Kuromatsu, R., El-Rayes, B., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.047 · Cited by 232
(2008) · Cited by 225
Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma
Rich, N. E., Hester, C., Odewole, M., Murphy, C. C., Parikh, N. D., Marrero, J. A., Yopp, A. C., & Singal, A. G. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.039 · Cited by 214
Disparities in liver cancer occurrence in the United States by race/ethnicity and state
Islami, F., Miller, K. D., Siegel, R. L., Fedewa, S. A., Ward, E. M., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21402 · Cited by 207
Qin, S., Chen, Z., Fang, W., Ren, Z., Xu, R., Ryoo, B.-Y., Meng, Z., Bai, Y., Chen, X., Liu, X., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00620 · Cited by 195
Cheng, A.-L., Qin, S., Ikeda, M., Galle, P., Ducreux, M., Zhu, A., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz446.002 · Cited by 194
Self-citationFinn, R. S., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.031 · Cited by 186
Self-citationNordness, M. F., Hamel, S., Godfrey, C. M., Shi, C., Johnson, D. B., Goff, L. W., O’Dell, H., Perri, R. E., & Alexopoulos, S. P. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15617 · Cited by 169
Self-citationPD-1 inhibitor as bridge therapy to liver transplantation?
Tabrizian, P., Florman, S. S., & Schwartz, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16448 · Cited by 163
Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer
Jacobs, J. M., Pensak, N. A., Sporn, N. J., MacDonald, J. J., Lennes, I. T., Safren, S. A., Pirl, W. F., Temel, J. S., & Greer, J. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.019729 · Cited by 162
DeLeon, T. T., Salomao, M. A., Aqel, B. A., Sonbol, M. B., Yokoda, R. T., Ali, A. H., Moss, A. A., Mathur, A. K., Chascsa, D. M., Rakela, J., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.07.05 · Cited by 157
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Kudo, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i7.789 · Cited by 148
Mathur, A. K., Osborne, N. H., Lynch, R., Ghaferi, A. A., Dimick, J. B., & Sonnenday, C. J. (2010) · Archives of Surgery · doi:10.1001/archsurg.2010.272 · Cited by 146
Friend, B. D., Venick, R. S., McDiarmid, S. V., Zhou, X., Naini, B. V., Wang, H., Farmer, D. G., Busuttil, R. W., & Federman, N. C. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26682 · Cited by 135
Xie, E., Yeo, Y. H., Scheiner, B., Zhang, Y., Hiraoka, A., Tantai, X., Fessas, P., de Castro, T., D’Alessio, A., Fulgenzi, C. A. M., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.3284 · Cited by 109
Self-citationHa, J. Y., Yan, M., Aguilar, M. E. F., Bhuket, T. P., Tana, M. M.-S., Liu, B., Gish, R. G., & Wong, R. J. (2016) · Cancer · doi:10.1002/cncr.30103 · Cited by 108
McNamara, M. G., Slagter, A. E., Nuttall, C., Frizziero, M., Pihlak, R., Lamarca, Á., Tariq, N., Valle, J. W., Hubner, R. A., Knox, J. J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.031 · Cited by 107
Kambhampati, S., Bauer, K., Bracci, P. M., Keenan, B. P., Behr, S. C., Gordan, J. D., & Kelley, R. K. (2019) · Cancer · doi:10.1002/cncr.32206 · Cited by 105
Self-citationMuluneh, B., Schneider, M., Faso, A., Amerine, L. B., Daniels, R., Crisp, B., Valgus, J. M., & Savage, S. (2018) · Journal of Oncology Practice · doi:10.1200/jop.17.00039 · Cited by 103
Parikh, N. D., Marshall, V. D., Singal, A. G., Nathan, H., Lok, A. S.-F., Balkrishnan, R., & Shahinian, V. B. (2016) · Hepatology · doi:10.1002/hep.28881 · Cited by 91
Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation
Yoon, D. H., Ryoo, B., Ryu, M.-H., Lee, S.-G., Hwang, S. M., Suh, D. J., Lee, H.-C., Kim, T. W., Ahn, C. S., Kim, K.-H., et al. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq055 · Cited by 86
Parikh, N. D., Singal, A. G., & Hutton, D. W. (2017) · Cancer · doi:10.1002/cncr.30863 · Cited by 85
Kobayashi, M., Kudo, M., Izumi, N., Kaneko, S., Azuma, M. K., Copher, R. M., Meier, G., Pan, J., Ishii, M., & Ikeda, S. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01554-0 · Cited by 84
Health care costs associated with hepatocellular carcinoma: A population-based study
Thein, H., Isaranuwatchai, W., Campitelli, M. A., Feld, J. J., Yoshida, E. M., Sherman, M., Hoch, J. S., Peacock, S. J., Krahn, M. D., & Earle, C. C. (2013) · Hepatology · doi:10.1002/hep.26231 · Cited by 80
Alpert, A. B., Gampa, V., Lytle, M. C., Manzano, C., Ruddick, R., Poteat, T., Quinn, G. P., & Kamen, C. S. (2021) · Patient Education and Counseling · doi:10.1016/j.pec.2021.03.007 · Cited by 73
Kaplan, D. E., Chapko, M. K., Mehta, R. L., Dai, F., Skanderson, M., Aytaman, A., Baytarian, M. L., D’Addeo, K., Fox, R. K., Hunt, K. K., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.07.024 · Cited by 66
Self-citationJost‐Brinkmann, F., Demir, M., Wree, A., Luedde, T., Loosen, S. H., Müller, T., Tacke, F., Roderburg, C., & Mohr, R. U. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17441 · Cited by 66
Shlomai, A., Leshno, M., & Goldstein, D. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207132 · Cited by 57
Roessler, D., Öcal, O., Philipp, A. B., Markwardt, D., Munker, S., Mayerle, J. V., Jochheim, L. S., Hammer, K., Lange, C. M., Geier, A., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04206-8 · Cited by 56
Paolella, G., Boyd, A., Wirth, S., Cuéllar, S., Venepalli, N. K., & Crawford, S. Y. (2018) · Pharmacy · doi:10.3390/pharmacy6010023 · Cited by 55
Liao, W., Huang, J., Hutton, D. W., Zhu, G., Wu, Q., Wen, F., Bai, L., & Li, Q. (2019) · Liver International · doi:10.1111/liv.14257 · Cited by 55
Amjad, W., Kotiah, S. D., Gupta, A., Morris, M. J., Liu, L., & Thuluvath, P. J. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.11.009 · Cited by 49
Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
Soto‐Pérez‐de‐Celis, E., Aguiar, P. N., Cordon, M. L., Chávarri-Guerra, Y., & Lopes, G. D. L., Jr. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7275 · Cited by 44
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
Alden, S. L., Lim, M., Kao, C., Shu, D. H., Singal, A. G., Noonan, A. M., Griffith, P., Baretti, M., Ho, W. J., Kamel, I. R., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0072 · Cited by 43
Self-citationAtezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
Cheon, J., Kim, H., Kim, H. S., Kim, C. G., Kim, I. H., Kang, B., Kim, C., Jung, S., Ha, Y., & Chon, H. J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148541 · Cited by 36
Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India
Gupta, N. M., Verma, R. K., Prinja, S., & Dhiman, R. K. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.10.003 · Cited by 27
Hirao, C., Mikoshiba, N., Shibuta, T., Yamahana, R., Kawakami, A., Tateishi, R., Yamaguchi, H., Koike, K., & Yamamoto‐Mitani, N. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx087 · Cited by 26
Sinner, F., Pinter, M., Scheiner, B., Ettrich, T. J., Sturm, N., Gonzalez-Carmona, M. A., Waidmann, O., Finkelmeier, F., Himmelsbach, V., Toni, E. N. D., et al. (2022) · Cancers · doi:10.3390/cancers14235966 · Cited by 25
Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
Shlomai, A., Leshno, M., & Goldstein, D. A. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819878304 · Cited by 23
(2021) · Default Digital Object Group · doi:10.1200/adn.21.200433 · Cited by 23
Motomura, K., Kuwano, A., Tanaka, K., Koga, Y., Masumoto, A., & Yada, M. (2023) · Cancers · doi:10.3390/cancers15174345 · Cited by 17
Labeur, T. A., ten Cate, D. W. G., Takkenberg, R. B., Azahaf, H., van Oijen, M. G. H., van Delden, O. M., de Man, R. A., van Vugt, J. L. A., IJzermans, J. N. M., Eskens, F. A. L. M., et al. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1479070 · Cited by 15
Elsisi, G. H., Nada, Y., Rashad, N., & Carapinha, J. L. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1552432 · Cited by 15
Kim, H. J., Hwang, S. Y., Im, J. W., Jeon, G. J., & Jeon, W. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2023.02.23 · Cited by 5
Cited by
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V., Mehta, N., Parikh, N. D., Abou-Alfa, G. K., Singal, A. G., & Yang, J. D. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 306
Self-citation
Metadata
- Authors
- Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beal, E., Finn, R. S., Gade, T. P., Goff, L., Gupta, S., Guy, J., Hoang, H. T., Iyer, R., Jaiyesimi, I., Jhawer, M., Karippot, A., Kaseb, A. O., Kelley, R. K., Kortmansky, J., Leaf, A., Remak, W. M., Sohal, D. P. S., Taddei, T. H., Wilson Woods, A., Yarchoan, M., & Rose, M. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2024-05-20
- Volume
- 42
- Issue
- 15
- Pages
- 1830-1850
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4392938370
- Cited by
- 312
- References
- 91
- FWCI
- 69.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.